Mercury Pharmaceuticals

19

Oct 2025

Low-calorie diets linked to higher psoriatic arthritis risk, genetic study suggests

This Mendelian randomization study found that low-calorie diets may slightly increase the risk of psoriatic arthritis, while vegetarian and gluten-free diets showed no causal links to psoriasis, acne, or atopic dermatitis. The findings challenge assumptions about universally beneficial dietary patterns and highlight the need for cautious interpretation of dietary interventions in inflammatory skin disease.

READ MORE

19

Oct 2025

MRI age clocks reveal how each organ ages differently and predict who develops disease or lives longer

Researchers developed seven MRI-based biological age clocks across major organs using UK Biobank imaging, linking each to proteins, metabolites, genetics, disease risks, mortality, and cognitive decline. These organ-specific age gaps reveal how uneven aging shapes vulnerability to conditions such as diabetes, hypertension, and dementia, opening new paths for precision prevention and clinical trial stratification

READ MORE

18

Oct 2025

CogLinks model reveals how the brain adapts to changing rules

Every day, your brain makes thousands of decisions under uncertainty. Most of the time, you guess right. When you don't, you learn. But when the brain's ability to judge context or assign meaning falters, thoughts and behavior can go astray.

READ MORE

18

Oct 2025

Children with multiple long-term conditions face nearly threefold higher COVID-19 mortality

Individuals with multiple long-term conditions are two and a half times more likely to die following COVID-19 infection than others.

READ MORE

18

Oct 2025

Belzutifan demonstrates strong clinical activity in two rare neuroendocrine tumors

A multicenter Phase II clinical trial led by researchers at The University of Texas MD Anderson Cancer Center demonstrated significant tumor shrinkage and disease control in patients with advanced pheochromocytoma and paraganglioma (PPGL), two rare and potentially life-threatening neuroendocrine tumors.

READ MORE

18

Oct 2025

Oral combination regimen improves survival in ER-positive HER-2-negative breast cancer

Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a novel, next-generation selective estrogen receptor degrader and full antagonist, compared to a standard combination approach.

READ MORE

18

Oct 2025

Targeted therapy combination shows superior outcomes in advanced kidney cancer

Results from a trial led by researchers from The University of Texas MD Anderson Cancer Center showed that a targeted therapy combination improved outcomes for patients with metastatic clear-cell renal carcinoma (ccRCC) – a type of kidney cancer – whose disease progressed following immunotherapy.

READ MORE

18

Oct 2025

New antibody drug conjugates can transform early HER2-positive breast cancer treatment

In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents-antibody-drug conjugates (ADCs)-can dramatically improve outcomes for patients with early-stage HER2-positive breast cancer.

READ MORE

17

Oct 2025

Nanoparticles offer new hope for treating alcohol-related liver disease

Across the world, more than 1.5 billion people suffer from chronic liver disease. The U.S. Centers for Disease Control and Prevention reports that it kills more than 52,000 people a year in the United States alone - the ninth most common cause of death in the nation.

READ MORE

17

Oct 2025

Nanoplastics with environmental coatings can sneak past the skin's defenses

Plastic is ubiquitous in the modern world, and it's notorious for taking a long time to completely break down in the environment - if it ever does.

READ MORE